Do anti-Yo antibodies indicate a cancer-associated subacute cerebellar syndrome rather than isolated cognitive decline?

The claim is well supported. Anti-Yo/PCA-1 identifies an immune-mediated, cancer-associated neurologic syndrome in which the expected presentation is rapidly progressive cerebellar dysfunction, not cognitive decline alone.

Clinical evidence

• Anti-Yo is a high-risk onconeural antibody strongly associated with paraneoplastic cerebellar degeneration (now termed rapidly progressive cerebellar syndrome in PNS-Care criteria). The syndrome generally evolves over days to weeks, and by definition reaches severe bilateral cerebellar dysfunction within <3 months.
• Typical findings include gait and truncal/limb ataxia, dysarthria, and ocular-motor abnormalities. MRI can be unrevealing early in the illness.
• The cancer association exceeds 90% in anti-Yo paraneoplastic cerebellar degeneration, with breast adenocarcinoma and ovarian/other gynecologic cancers predominating. In a clinically concordant syndrome, anti-Yo should prompt focused malignancy evaluation.
• Cognitive symptoms—memory difficulties, emotional lability, or rarely cerebellar cognitive-affective syndrome—can accompany the disorder, but are usually not the dominant or isolated presentation. Isolated cognitive decline should prompt assessment for other neurologic, systemic, toxic-metabolic, medication-related, vascular, metastatic, infectious, or extracerebellar paraneoplastic causes.

Mechanistic and diagnostic considerations

• CDR2L is the best-supported dominant native Yo antigen in Purkinje cells; CDR2 is an additional target in some patients. Anti-Yo/PCA-1 tissue staining characteristically involves Purkinje-cell somata and dendrites.
• Because these antigens are intracellular, CD8-positive cytotoxic T cells are considered principal mediators of Purkinje-cell death; antibodies are important biomarkers and may contribute to dysfunction but are unlikely to be the sole effector.
• Isolated low-titer commercial line-blot serum positivity can be false positive. Serum and CSF testing with tissue-based confirmation plus antigen-specific CDR2/CDR2L assays provides more reliable interpretation.

Bottom line

• Anti-Yo strongly supports a cancer-associated, subacute cerebellar syndrome when phenotype and confirmatory testing align; it does not make isolated cognitive decline the expected presentation.